In this episode, Dr. Hind Rafei dives into the cutting-edge world of CAR-NK cell therapy and its potential to revolutionize cancer treatment. Unlike their T-cell counterparts, CAR-NK cells promise enhanced safety and innate tumor-killing ability. But what if their power could be dialed up even further?

Dr. Rafei discusses her team's groundbreaking discovery of CREM, a transcriptional regulator that shapes CAR-NK function and limits its full therapeutic potential. We explore how modulating CREM—particularly by deleting or suppressing it—can reprogram these cells to become more effective, resilient cancer fighters.

We unpack the science behind the PKA–CREB pathway, CREM-driven epigenetic changes, and how these findings might lead to next-generation immunotherapies and even cancer vaccines. Finally, Dr. Rafei offers insights on clinical translation and the path ahead for CREM-tuned therapies.

Whether you’re a researcher, clinician, or patient advocate, this episode sheds light on one of the most promising frontiers in cellular immunotherapy.

• #CARNKCells

• #CellTherapy

• #CancerImmunotherapy

• #GeneEditing

• #Epigenetics

• #TranscriptionFactors

• #CREMgene

• #CancerBiology

• #ImmunoOncology

• #NextGenTherapies

• #CancerInnovation

• #PodcastEpisode

• #SciencePodcast

• #MedicalPodcast

• #CancerResearch

• #Immunotherapy